More MS news articles for April 2002

Chemokines as novel therapeutic targets in inflammatory diseases

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11960595&dopt=Abstract

Biochem Pharmacol 2002 Apr 1;63(7):1191-6
Ajuebor MN, Swain MG, Perretti M.
Liver Unit, Gastrointestinal Research Group, Faculty of Medicine, University of Calgary, 3330 Hospital Drive, Alta., T2N 4N1, Calgary, Canada

Chemokines and their receptors are a large family of inflammatory molecules responsible for a number of biological functions, including the accumulation of leukocytes at tissue sites.

Over the past 10 years, a number of studies have indicated a role for chemokines and chemokine receptors in the pathophysiology of several inflammatory diseases, examples of which are multiple sclerosis, atherosclerosis, rheumatoid arthritis, and gastrointestinal diseases including hepatic disease.

For this reason, it is not surprising that modulation of their pharmacology could be a prime target for drug discovery.

This commentary provides a brief synopsis of our current knowledge of the role of chemokines and their receptors in the inflammatory process, and highlights the pros and possibly cons of chemokine and chemokine receptor antagonism in the therapeutic approach to several inflammatory diseases.